IXC's Principal Activity is the biopharmaceuticals.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-46.23%|
|vs ASX 200 (1yr)||-59.71%|
|ASX Rank||1,331 of 2,295|
|Sector Rank||115 of 177|
Invex Therapeutics Ltd (IXC) is a biopharmaceutical company focused on the repurposing of an approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised intracranial pressure, such as Idiopathic Intracranial Hypertension (IIH), acute stroke and traumatic brain injury. Invex has trademarked its repurposed Exenatide as Presendin.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Dr Megan Baldwin||Non-Executive Director||Feb 2021||
Dr Megan Baldwin
Dr Baldwin is an experienced biotechnology executive, having over 20 years' experience working on therapeutic drug development programs for cancer and ophthalmic indications. Dr Baldwin is CEO and Managing Director of Opthea Limited (ASX: OPT; NASDAQ: OPT), a biopharmaceutical company developing a novel therapy to address the unmet need in the treatment of retinal eye diseases, including wet age-related macular degeneration (wet AMD). Under Dr Baldwin's leadership, Opthea has advanced its ophthalmology program through Phase I and Phase II clinical development. It was added to the S&P/ASX 300 in June 2020 and in October 2020 completed initial public offering (IPO) and listing on the US NASDAQ exchange to progress two pivotal Phase III studies in wet AMD. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech as Deputy Chair.
|Dr Thomas (Tom) Duthy||Executive Director||Oct 2020||
Dr Thomas (Tom) Duthy
Dr Duthy has financial market experience, combined with his senior executive experience at the S&P/ASX Top 100 Company level and involvement in corporate transactions within the sector. Dr Duthy is currently the CEO of Nemean Group Pty Ltd, a boutique corporate advisory and investor relations (IR) firm based in Adelaide, Australia. Dr Duthy was formerly the Global Head of Investor Relations & Corporate Development at Sirtex Medical Limited (Sirtex), which was sold to CDH Investments in September 2018. He currently advises several ASX Listed companies in both IR and Corporate Development roles. Prior to Sirtex, Dr Duthy spent ten years as a sell-side Healthcare & Biotechnology analyst focused mainly on small cap companies. Dr Duthy is currently a Non-Executive Director of Respiri Limited.
|Dr Alexandra J Sinclair||Chief Scientific Officer,Executive Director||Jun 2019||
Dr Alexandra J Sinclair
Chief Scientific Officer,Executive Director
Dr Sinclair is a Clinician Scientist and Neurology Consultant in the Metabolic Neurology Group at the Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, The University of Birmingham, UK.
|Mrs Narelle Warren||Chief Financial Officer,Company Secretary||Mar 2019||
Mrs Narelle Warren
Chief Financial Officer,Company Secretary
Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has co-ordinated and assisted in a number of corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.
|Mr David McAuliffe||Non-Executive Director||Mar 2019||
Mr David McAuliffe
Mr McAuliffe has over twenty years' experience in the international biotechnology field. He has been involved in capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France and the United Kingdom, many of which have become public companies. He is President of the Dyslexia-Speld Foundation WA (Inc). Mr McAuliffe is a current director of ASX listed 4DS Memory Ltd.
|Dr Jason Loveridge||Non-Executive Chairman,Non-Executive Director||Mar 2019||
Dr Jason Loveridge
Non-Executive Chairman,Non-Executive Director
Dr Loveridge is a founder of Invex and currently CEO of 4SC AG, a Frankfurt (Germany) listed oncology company. He has more than thirty years of international experience across Europe, Asia and the US in senior management positions in life sciences companies and as an investment professional dealing in both privately held and publicly traded companies. Additionally, he has transactional experience in the sale and partnering of biotechnology assets.
IXC directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|08/04/21||Megan Baldwin||Issued||400,000||$0.775||$310,000||Issue of options|
|18/11/20||Thomas (Tom) Duthy||Issued||800,000||$0.805||$644,000||Issue of options|
|22/11/19||Alexandra Sinclair||Issued||800,000||$0.71||$568,000||Issue of options|
|22/11/19||David McAuliffe||Issued||200,000||$0.71||$142,000||Issue of options|
|22/11/19||Jason Loveridge||Issued||800,000||$0.71||$568,000||Issue of options|
|22/11/19||Narelle Warren||Issued||400,000||$0.71||$284,000||Issue of options|
The current holdings of IXC directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
|Thomas (Tom) Duthy||18/11/2020||N/A||106,923||800,000||N/A|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Tattarang Pty Ltd||27/08/2020||8,846,154||11.77|
|Tisia Nominees Pty Ltd||27/08/2020||4,000,000||5.32|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|01-12-20||JK Nominees Pty Ltd||4,000,000||5.92||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.